Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Phase 2 Completed
21 enrolled 24 charts
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
Phase 2 Completed
18 enrolled 10 charts
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Phase 2 Completed
40 enrolled 21 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
MOHEL
Phase 2 Completed
46 enrolled 12 charts
ALBUM
Phase 2 Completed
16 enrolled 7 charts
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Phase 1/2 Completed
92 enrolled 28 charts
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Phase 1/2 Terminated
8 enrolled 9 charts
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Phase 2 Completed
35 enrolled 11 charts
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
12 enrolled 10 charts
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
1 enrolled 5 charts
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
Phase 2 Terminated
7 enrolled 6 charts
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Terminated
14 enrolled 7 charts
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Phase 2 Completed
204 enrolled 7 charts
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Phase 1/2 Terminated
4 enrolled 8 charts
REGALE
Phase NA Terminated
24 enrolled 7 charts
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Terminated
16 enrolled 6 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2 Completed
51 enrolled 11 charts